GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » Debt-to-EBITDA

Item 9 Labs (Item 9 Labs) Debt-to-EBITDA : -3.39 (As of Jun. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Item 9 Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $34.15 Mil. Item 9 Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.15 Mil. Item 9 Labs's annualized EBITDA for the quarter that ended in Jun. 2023 was $-10.12 Mil. Item 9 Labs's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -3.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Item 9 Labs's Debt-to-EBITDA or its related term are showing as below:

INLB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.81   Med: -0.53   Max: -0.04
Current: -1.73

During the past 13 years, the highest Debt-to-EBITDA Ratio of Item 9 Labs was -0.04. The lowest was -4.81. And the median was -0.53.

INLB's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs INLB: -1.73

Item 9 Labs Debt-to-EBITDA Historical Data

The historical data trend for Item 9 Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs Debt-to-EBITDA Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.53 -1.77 -4.81 -1.22

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 -0.45 -8.51 -9.93 -3.39

Competitive Comparison of Item 9 Labs's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Debt-to-EBITDA falls into.



Item 9 Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Item 9 Labs's Debt-to-EBITDA for the fiscal year that ended in Sep. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.946 + 7.899) / -22.829
=-1.22

Item 9 Labs's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(34.15 + 0.145) / -10.124
=-3.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


Item 9 Labs  (OTCPK:INLB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Item 9 Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Item 9 Labs (Item 9 Labs) Business Description

Traded in Other Exchanges
N/A
Address
2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
Executives
Taylor Lawrence X. Iii director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey director C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden director C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven officer: Chief Operating Officer 5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson director, officer: Chief Executive Officer 1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden director 3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen officer: CFO, Secretary, Treasurer 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan 10 percent owner 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier 10 percent owner 1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla director, officer: President 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md director, officer: President 10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership director, officer: President & CEO 10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith officer: CFO, Secretary, Treasurer 8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson officer: Chief Operating Officer 8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251